Sign In
Buy IKNA
$1.43
+0 (+0%)
At Close: Oct 24, 2025
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
11:00am, Friday, 25'th Jul 2025
The combined company will operate under the name “ImageneBio, Inc.” and will begin trading on Nasdaq under the ticker symbol “IMA” at market open on Monday, July 28, 2025
Ikena Oncology and Inmagene Biopharmaceuticals Announce Kristin Yarema, Ph.D., as Chief Executive Officer of Merged Company
09:00am, Wednesday, 23'rd Jul 2025
BOSTON and SAN DIEGO, July 23, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced the appointment of Kristin Ya
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
04:15pm, Tuesday, 15'th Jul 2025
Combined Company to Trade on Nasdaq Under Ticker “IMA” Ikena Announces 1-for-12 Reverse Stock Split of Ikena Common Stock BOSTON and SAN DIEGO, July 15, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, In
Ikena Oncology Announces ISS and Glass Lewis Recommend Stockholders Vote “FOR” Proposed Merger with Inmagene Biopharmaceuticals
08:00am, Friday, 11'th Jul 2025
BOSTON, July 11, 2025 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” the “Company”) today announced that Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade
01:01pm, Monday, 30'th Dec 2024
Ikena Oncology (IKNA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
08:37am, Monday, 23'rd Dec 2024
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
08:30am, Monday, 23'rd Dec 2024
Inmagene Biopharmaceuticals is a clinical stage company focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody with an extended half-life and a silenced ADCC function
Ikena Oncology Reports Third Quarter 2024 Financial Results
08:30am, Thursday, 07'th Nov 2024
Strong financial position with $138 million in cash and investments at close of third quarter Strong financial position with $138 million in cash and investments at close of third quarter
Ikena Oncology Reports Second Quarter 2024 Financial Results
04:15pm, Thursday, 08'th Aug 2024
Strong financial position with $145 million in cash and investments at close of second quarter Strong financial position with $145 million in cash and investments at close of second quarter
Best Momentum Stocks to Buy for July 12th
11:15am, Friday, 12'th Jul 2024
IKNA, AVAH, and VEL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 12, 2024.
New Strong Buy Stocks for July 12th
07:40am, Friday, 12'th Jul 2024
USAC, NHYDY, APOG, IKNA, and CRGY have been added to the Zacks Rank #1 (Strong Buy) List on July 12, 2024.
UPDATE – Ikena Oncology Announces Strategic Update
04:42pm, Tuesday, 28'th May 2024
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Explorin
Ikena Oncology Announces Strategic Update
04:15pm, Tuesday, 28'th May 2024
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Explorin
Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
04:45pm, Monday, 13'th May 2024
Strong financial position with $157.3 million; runway into 2H 2026 IK-930 program on track to deliver clinical update in 2H 2024 IK-595 program continues dose escalation in patients with RAS and RAF m
Ikena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology Forum
08:00am, Wednesday, 10'th Apr 2024
BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, toda
